



BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update

April 30, 2019

Conference Call scheduled on May 7, 2019 at 8:30 AM EDT

NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it plans to release its financial results for the first quarter 2019 ended March 31, 2019 on Tuesday, May 7, 2019. BTI plans to hold a conference call at 8:30 AM Eastern Time on Tuesday, May 7, 2019 to discuss the financial results and provide a business update.

CONFERENCE CALL & WEBCAST

Tuesday, May 7, 2019, 8:30 AM Eastern Time

Domestic: 1-888-394-8218

International: 1-323-794-2588

Conference ID: 9482739

Webcast: <http://public.viavid.com/index.php?id=134360>

Replay – Available through June 7, 2019

Domestic: 1-844-512-2921

International: 1-412-317-6671

Conference ID: 9482739

About BioXcel Therapeutics, Inc. (BTI):

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.

Contact Information:

The Ruth Group for BTI:

Lee Roth / Janhavi Mohite

646-536-7012 / 7026

lroth@theruthgroup.com / jmohite@theruthgroup.com

Source: BioXcel Therapeutics, Inc.